Michael Wang, MD, discusses the pharmacological profile of KTE-X19 in patients with high- or low-risk relapsed/refractory mantle cell lymphoma in the ZUMA-2 trial.
Michael Wang, MD, a professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses the pharmacological profile of KTE-X19 in patients with high- or low-risk relapsed/refractory mantle cell lymphoma (MCL) in the ZUMA-2 trial (NCT02601313).
In this phase 2 trial, investigators wanted to see whether the chimeric antigen receptor (CAR) T-cell expansion would be similar between patients with high-risk and low-risk disease. The results showed the efficacy was the same for these groups. According to Wang, finding that the efficacy was the same for the patients with low-risk MCL is important because there is now underlying data to correspond to the observation that low-risk and high-risk disease react the same with a CAR T-cell therapy such as KTE-X19; therefore, an anti-CD19 CAR T-cell therapy can overcome high-risk resistance in patients. In his opinion, this is powerful data for this setting.
The pharmacodynamic profiles between patients with low- and high-risk MCL were shown in the poster presented during the 2020 American Society of Clinical Oncology Virtual Scientific Program. Wang says there was a small trend between increased cytokines in the high-risk group, but there was not a statistical difference.